Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
Study Type
OBSERVATIONAL
Enrollment
3,000
Proportion of patients who experience specified events
To collect and evaluate safety and effectiveness data specific to the use of eculizumab or ravulizumab in aHUS patients.
Time frame: 10 years
Time to first and subsequent occurrence of specified events.
To assess the long term manifestations of thrombotic microangiopathy (TMA) complications of aHUS as well as other clinical outcomes, including morbidity and mortality in aHUS patients, receiving eculizumab or ravulizumab treatment or other disease management approaches
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Trial Site
Aurora, Colorado, United States
RECRUITINGClinical Trial Site
Washington D.C., District of Columbia, United States
RECRUITINGClinical Trial Site
Gainesville, Florida, United States
RECRUITINGClinical Trial Site
Atlanta, Georgia, United States
RECRUITINGClinical Trial Site
Chicago, Illinois, United States
WITHDRAWNClinical Trial Site
Boston, Massachusetts, United States
RECRUITINGClinical Trial Site
St Louis, Missouri, United States
RECRUITINGClinical Trial Site
Winston-Salem, North Carolina, United States
WITHDRAWNClinical Trial Site
Columbus, Ohio, United States
ACTIVE_NOT_RECRUITINGClinical Trial Site 1
Westmead, New South Wales, Australia
RECRUITING...and 131 more locations